1512 related articles for article (PubMed ID: 33546958)
1. COVID-19 in patients with cancer: Risks and precautions.
Razavi A; Hamblin MR; Rezaei N
Am J Emerg Med; 2021 Oct; 48():357-360. PubMed ID: 33546958
[TBL] [Abstract][Full Text] [Related]
2. Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy.
Hong R; Zhao H; Wang Y; Chen Y; Cai H; Hu Y; Wei G; Huang H
Bone Marrow Transplant; 2021 Mar; 56(3):570-580. PubMed ID: 32943758
[TBL] [Abstract][Full Text] [Related]
3. Optimizing Administration of CAR T-Cell Therapy During the COVID-19 Pandemic.
Bishop MR
Clin Adv Hematol Oncol; 2020 Jul; 18(7):400-403. PubMed ID: 32903251
[No Abstract] [Full Text] [Related]
4. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
Madduri D; Parekh S; Campbell TB; Neumann F; Petrocca F; Jagannath S
J Med Case Rep; 2021 Feb; 15(1):90. PubMed ID: 33608053
[TBL] [Abstract][Full Text] [Related]
5. The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden.
Santomasso B; Bachier C; Westin J; Rezvani K; Shpall EJ
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():433-444. PubMed ID: 31099694
[TBL] [Abstract][Full Text] [Related]
6. Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration.
Chen R; Lan Z; Ye J; Pang L; Liu Y; Wu W; Qin X; Guo Y; Zhang P
Front Immunol; 2021; 12():589095. PubMed ID: 33995341
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
Front Immunol; 2021; 12():611366. PubMed ID: 33708205
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report.
McNerney KO; Richards RM; Aguayo-Hiraldo P; Calkoen FG; Talano JA; Moskop A; Balduzzi A; Krajewski J; Dave H; Vatsayan A; Callahan C; Liu H; Li Y; Davis KL; Maude SL
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36707090
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
Wei J; Zhao J; Han M; Meng F; Zhou J
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
[TBL] [Abstract][Full Text] [Related]
10. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
11. Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?
Frigault MJ; Nikiforow S; Mansour MK; Hu ZH; Horowitz MM; Riches ML; Hematti P; Turtle CJ; Zhang MJ; Perales MA; Pasquini MC
Blood; 2020 Jul; 136(1):137-139. PubMed ID: 32457999
[No Abstract] [Full Text] [Related]
12. Reactions Related to CAR-T Cell Therapy.
Miao L; Zhang Z; Ren Z; Li Y
Front Immunol; 2021; 12():663201. PubMed ID: 33995389
[TBL] [Abstract][Full Text] [Related]
13. Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy.
Li X; Shao M; Zeng X; Qian P; Huang H
Signal Transduct Target Ther; 2021 Oct; 6(1):367. PubMed ID: 34667157
[TBL] [Abstract][Full Text] [Related]
14. A SARS-CoV-2-specific CAR-T-cell model identifies felodipine, fasudil, imatinib, and caspofungin as potential treatments for lethal COVID-19.
Xia L; Yuan LZ; Hu YH; Liu JY; Hu GS; Qi RY; Zhang TY; Xiong HL; Zheng ZZ; Lin HW; Zhang JM; Yu C; Zhou M; Ma J; Cheng T; Chen RR; Guan Y; Xia NS; Liu W
Cell Mol Immunol; 2023 Apr; 20(4):351-364. PubMed ID: 36864189
[TBL] [Abstract][Full Text] [Related]
15. The cytokine storm and COVID-19.
Hu B; Huang S; Yin L
J Med Virol; 2021 Jan; 93(1):250-256. PubMed ID: 32592501
[TBL] [Abstract][Full Text] [Related]
16. Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor TÂ cell immunotherapy recipients.
Sesques P; Bachy E; Ferrant E; Safar V; Gossez M; Morfin-Sherpa F; Venet F; Ader F
Cancer Cell; 2022 Mar; 40(3):236-237. PubMed ID: 35093212
[No Abstract] [Full Text] [Related]
17. CD8
Bange EM; Han NA; Wileyto P; Kim JY; Gouma S; Robinson J; Greenplate AR; Hwee MA; Porterfield F; Owoyemi O; Naik K; Zheng C; Galantino M; Weisman AR; Ittner CAG; Kugler EM; Baxter AE; Oniyide O; Agyekum RS; Dunn TG; Jones TK; Giannini HM; Weirick ME; McAllister CM; Babady NE; Kumar A; Widman AJ; DeWolf S; Boutemine SR; Roberts C; Budzik KR; Tollett S; Wright C; Perloff T; Sun L; Mathew D; Giles JR; Oldridge DA; Wu JE; Alanio C; Adamski S; Garfall AL; Vella LA; Kerr SJ; Cohen JV; Oyer RA; Massa R; Maillard IP; Maxwell KN; Reilly JP; Maslak PG; Vonderheide RH; Wolchok JD; Hensley SE; Wherry EJ; Meyer NJ; DeMichele AM; Vardhana SA; Mamtani R; Huang AC
Nat Med; 2021 Jul; 27(7):1280-1289. PubMed ID: 34017137
[TBL] [Abstract][Full Text] [Related]
18. Innate Receptor Activation Patterns Involving TLR and NLR Synergisms in COVID-19, ALI/ARDS and Sepsis Cytokine Storms: A Review and Model Making Novel Predictions and Therapeutic Suggestions.
Root-Bernstein R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672738
[TBL] [Abstract][Full Text] [Related]
19. IL-6: from arthritis to CAR-T-cell therapy and COVID-19.
Kishimoto T
Int Immunol; 2021 Sep; 33(10):515-519. PubMed ID: 33715009
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil Extracellular Traps (NETs) and Covid-19: A new frontiers for therapeutic modality.
Al-Kuraishy HM; Al-Gareeb AI; Al-Hussaniy HA; Al-Harcan NAH; Alexiou A; Batiha GE
Int Immunopharmacol; 2022 Mar; 104():108516. PubMed ID: 35032828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
